MOMO'S BREAKOUT BOARD

[dirkv]

All time low

Mirati Therapeutics, Inc. (MRTX): 4.75

52W 4.69 - 52
Market Cap (intraday) 93.43 M
Total Cash (mrq) 107.67M
SAN DIEGO, Sept. 15, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the pricing of an underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $45.00 per share. The gross proceeds from this offering are expected to be approximately $101.3 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati.
Total Cash Per Share (mrq) 5.41
Total Debt (mrq) 0

Time for a stong recovery
2016/07/19 5.34
2016/07/13 5.65
2016/07/11 5.87
2016/06/17 7.19
2016/06/10 9.41
2016/06/03 19.2523
2015/09/15 52.00

http://www.ftsenews.co.uk/2016/07/15/mirati-therapeutics-inc-mrtx-updated-price-targets-6/
lowest pricetarget: 14
Highest pricetarget: 32


Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of products targeting oncology. The company?s clinical stage product candidates include MGCD265, a multi-targeted kinase inhibitor that is in Phase 1b clinical development trials for the treatment of patients with non-small cell lung cancer and other solid tumors, such as those found in gastroesophageal cancers, and squamous cell carcinoma of the head and neck; and MGCD516, a kinase inhibitor, which is in Phase Ib clinical development for the treatment of solid tumors with an emphasis on genetic alterations. It also develops Mocetinostat, an orally-bioavailable histone deacetylase inhibitor that is in Phase 2 clinical trial development for patients with bladder cancer, myelodysplastic syndrome, and non-hodgkin's lymphoma, principally diffuse large B-cell lymphoma and follicular lymphoma. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for MGCD265; and a partnership with QIAGEN N.V. to develop and commercialize a companion diagnostic test to guide the use of glesatinib (MGCD265), a targeted therapy under development for non-small cell lung cancer. Mirati Therapeutics, Inc. is headquartered in San Diego, California.